Description: Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers medicines in various therapeutic areas, including gastroenterology; cancer; neurological and psychiatric diseases; and rare diseases, such as immunology and hematology, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Home Page: www.takeda.com
TAK Technical Analysis
1-1, Nihonbashi-Honcho 2-chome
Tokyo,
103-8668
Japan
Phone:
81 3 3278 2111
Officers
| Name | Title |
|---|---|
| Mr. Christophe Weber | Pres, CEO & Representative Director |
| Mr. Constantine Saroukos | CFO & Representative Director |
| Dr. Andrew S. Plump | Pres of R&D and Representative Director |
| Dr. Seigo Izumo | Chair of Management Board |
| Mr. Haruhiko Hirate | Member of Management Board |
| Salvatore Alesci | Member of Management Board and Head of R&D Global Science & Biomedical Policy |
| Norimasa Takeda | Chief Accounting Officer & Corp. Controller |
| Mr. Iwaaki Taniguchi | Sr. VP of Corp. Fin. & Controlling Department |
| Mr. Gabriele Ricci | Chief Data & Technology Officer |
| Mr. Christopher David O'Reilly | Global Head of Investor Relations & Global Fin. |
Exchange: NYSE
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 9.7276 |
|---|---|
| Trailing PE: | 29.6154 |
| Price-to-Book MRQ: | 0.9814 |
| Price-to-Sales TTM: | 0.0126 |
| IPO Date: | 2008-10-27 |
| Fiscal Year End: | March |
| Full Time Employees: | 47347 |